{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T01:45:52Z","timestamp":1790214352155,"version":"4.1.0"},"reference-count":37,"publisher":"American Society of Hematology","issue":"20","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2011,11,17]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>A total of 90% of follicular lymphomas (FLs) harbor the translocation t(14;18) leading to deregulated BCL2 expression. Conversely, 10% of FLs lack the t(14;18), and the majority of these FLs do not express BCL2. The molecular features of t(14;18)\u2013negative FLs remain largely unknown. We performed microRNA expression analysis in 32 FL grades 1 to 3A, including 17 t(14;18)\u2013positive FLs, 9 t(14;18)\u2013negative FLs without BCL2 expression, and 6 t(14;18)\u2013negative FLs with BCL2 expression. MicroRNA profiles were correlated with corresponding mRNA expression patterns, and potential targets were investigated by quantitative PCR and immunohistochemistry in an independent validation series of 83 FLs. Statistical analysis identified 17 microRNAs that were differentially expressed between t(14;18)\u2013positive FLs and t(14;18)\u2013negative FLs. The down-regulation of miR-16, miR-26a, miR-101, miR-29c, and miR138 in the t(14;18)-negative FL subset was associated with profound mRNA expression changes of potential target genes involving cell cycle control, apoptosis, and B-cell differentiation. miR-16 target CHEK1 showed increased expression in t(14;18)-negative FLs, whereas TCL1A expression was reduced, in line with a partial loss of the germinal center B-cell phenotype in this FL subset. In conclusion, t(14;18)\u2013negative FL have distinct microRNA profiles that are associated with an increased proliferative capacity and a \u201clate\u201d germinal center B-cell phenotype.<\/jats:p>","DOI":"10.1182\/blood-2011-06-361972","type":"journal-article","created":{"date-parts":[[2011,9,30]],"date-time":"2011-09-30T12:08:45Z","timestamp":1317384525000},"page":"5550-5558","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":78,"title":["MicroRNA profiles of t(14;18)\u2013negative follicular lymphoma support a late germinal center B-cell phenotype"],"prefix":"10.1182","volume":"118","author":[{"given":"Ellen","family":"Leich","sequence":"first","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zamo","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Verona, Verona, Italy;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Horn","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugenia","family":"Haralambieva","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernhard","family":"Puppe","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Randy D.","family":"Gascoyne","sequence":"additional","affiliation":[{"name":"British Columbia Cancer Agency, University of British Columbia, Vancouver, BC;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wing-Chung","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita M.","family":"Braziel","sequence":"additional","affiliation":[{"name":"Southwest Oncology Group, Oregon Health and Science University, Portland, OR;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Rimsza","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Arizona, Tucson, AZ;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dennis D.","family":"Weisenburger","sequence":"additional","affiliation":[{"name":"Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Delabie","sequence":"additional","affiliation":[{"name":"Division of Pathology, Norwegian Radium Hospital, Oslo, Norway;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elaine S.","family":"Jaffe","sequence":"additional","affiliation":[{"name":"Laboratory of Pathology, National Cancer Institute, National Institutes of Health (NIH), Bethesda, MD;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jude","family":"Fitzgibbon","sequence":"additional","affiliation":[{"name":"Cancer Research United Kingdom, St Bartholomew's Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis M.","family":"Staudt","sequence":"additional","affiliation":[{"name":"Metabolism Branch, National Cancer Institute, NIH, Bethesda, MD; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Konrad","family":"Mueller-Hermelink","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariarita","family":"Calaminici","sequence":"additional","affiliation":[{"name":"Cancer Research United Kingdom, St Bartholomew's Hospital, London, United Kingdom;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elias","family":"Campo","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"German","family":"Ott","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Robert-Bosch-Krankenhaus, and Dr Margarete Fischer-Bosch Institute of Clinical Pharmacology, Stuttgart, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Department of Pathology, Hospital Clinic, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Rosenwald","sequence":"additional","affiliation":[{"name":"Institute of Pathology, University of W\u00fcrzburg, W\u00fcrzburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111807233033700_B1","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"Swerdlow","year":"2008"},{"issue":"15","key":"2019111807233033700_B2","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.1200\/JCO.2006.06.4618","article-title":"Rituximab added to first-line mitoxantrone, chlorambucil, and prednisolone chemotherapy followed by interferon maintenance prolongs survival in patients with advanced follicular lymphoma: an East German Study Group Hematology and Oncology Study.","volume":"25","author":"Herold","year":"2007","journal-title":"J Clin Oncol"},{"issue":"26","key":"2019111807233033700_B3","doi-asserted-by":"crossref","first-page":"6394","DOI":"10.1200\/JCO.2005.07.019","article-title":"Treatment strategies in follicular lymphomas: current status and future perspectives.","volume":"23","author":"Hiddemann","year":"2005","journal-title":"J Clin Oncol"},{"issue":"4","key":"2019111807233033700_B4","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1182\/blood-2009-01-198580","article-title":"Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations.","volume":"114","author":"Leich","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2019111807233033700_B5","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1002\/(SICI)1098-2264(200001)27:1<85::AID-GCC11>3.0.CO;2-9","article-title":"Interphase FISH detection of BCL2 rearrangement in follicular lymphoma using breakpoint-flanking probes.","volume":"27","author":"Vaandrager","year":"2000","journal-title":"Genes Chromosomes Cancer"},{"issue":"12","key":"2019111807233033700_B6","doi-asserted-by":"crossref","first-page":"1822","DOI":"10.3324\/haematol.13239","article-title":"Somatic hypermutation of IGVH genes and aberrant somatic hypermutation in follicular lymphoma without BCL-2 gene rearrangement and expression.","volume":"93","author":"Gagyi","year":"2008","journal-title":"Haematologica"},{"issue":"2","key":"2019111807233033700_B7","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1182\/blood-2003-06-1901","article-title":"Prognostic significance of bcl-xL gene expression and apoptotic cell counts in follicular lymphoma.","volume":"103","author":"Zhao","year":"2004","journal-title":"Blood"},{"issue":"5A","key":"2019111807233033700_B8","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1111\/j.1582-4934.2008.00399.x","article-title":"MicroRNA expression in lymphoid malignancies: new hope for diagnosis and therapy?","volume":"12","author":"Lawrie","year":"2008","journal-title":"J Cell Mol Med"},{"issue":"7","key":"2019111807233033700_B9","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1111\/j.1582-4934.2008.00628.x","article-title":"Expression of microRNAs in diffuse large B cell lymphoma is associated with immunophenotype, survival and transformation from follicular lymphoma.","volume":"13","author":"Lawrie","year":"2009","journal-title":"J Cell Mol Med"},{"issue":"5","key":"2019111807233033700_B10","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1111\/j.1365-2141.2008.07237.x","article-title":"MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas.","volume":"142","author":"Roehle","year":"2008","journal-title":"Br J Haematol"},{"issue":"21","key":"2019111807233033700_B11","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells.","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"issue":"2","key":"2019111807233033700_B12","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.","volume":"42","author":"Morin","year":"2011","journal-title":"Nat Genet"},{"issue":"2","key":"2019111807233033700_B13","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1002\/path.1197","article-title":"Detection of three common translocation breakpoints in non-Hodgkin's lymphomas by fluorescence in situ hybridization on routine paraffin-embedded tissue sections.","volume":"198","author":"Haralambieva","year":"2002","journal-title":"J Pathol"},{"issue":"1","key":"2019111807233033700_B14","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/j.1349-7006.2009.01385.x","article-title":"Changes in microRNA expression levels correlate with clinicopathological features and prognoses in endometrial serous adenocarcinomas.","volume":"101","author":"Hiroki","year":"2010","journal-title":"Cancer Sci"},{"issue":"10","key":"2019111807233033700_B15","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1182\/blood-2008-03-147645","article-title":"MYC stimulates EZH2 expression by repression of its negative regulator miR-26a.","volume":"112","author":"Sander","year":"2008","journal-title":"Blood"},{"issue":"1","key":"2019111807233033700_B16","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ccr.2009.11.019","article-title":"The DLEU2\/miR-15a\/16\u20131 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia.","volume":"17","author":"Klein","year":"2010","journal-title":"Cancer Cell"},{"issue":"1","key":"2019111807233033700_B17","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1751-2980.2009.00413.x","article-title":"Initial study of microRNA expression profiles of colonic cancer without lymph node metastasis.","volume":"11","author":"Wang","year":"2010","journal-title":"J Dig Dis"},{"issue":"13","key":"2019111807233033700_B18","doi-asserted-by":"crossref","first-page":"2630","DOI":"10.1182\/blood-2009-09-243147","article-title":"microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma.","volume":"115","author":"Zhao","year":"2010","journal-title":"Blood"},{"issue":"3","key":"2019111807233033700_B19","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1158\/0008-5472.CAN-08-2886","article-title":"MicroRNA-101, down-regulated in hepatocellular carcinoma, promotes apoptosis and suppresses tumorigenicity.","volume":"69","author":"Su","year":"2009","journal-title":"Cancer Res"},{"issue":"6","key":"2019111807233033700_B20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.cell.2009.05.038","article-title":"New hope for a microRNA therapy for liver cancer.","volume":"137","author":"Rossi","year":"2009","journal-title":"Cell"},{"issue":"5","key":"2019111807233033700_B21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.jhep.2009.12.024","article-title":"The let-7 family of microRNAs inhibits Bcl-xL expression and potentiates sorafenib-induced apoptosis in human hepatocellular carcinoma.","volume":"52","author":"Shimizu","year":"2010","journal-title":"J Hepatol"},{"issue":"7","key":"2019111807233033700_B22","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1016\/j.cell.2007.04.040","article-title":"A mammalian microRNA expression atlas based on small RNA library sequencing.","volume":"129","author":"Landgraf","year":"2007","journal-title":"Cell"},{"issue":"19","key":"2019111807233033700_B23","doi-asserted-by":"crossref","first-page":"4586","DOI":"10.1182\/blood-2008-09-178186","article-title":"Patterns of microRNA expression characterize stages of human B-cell differentiation.","volume":"113","author":"Zhang","year":"2009","journal-title":"Blood"},{"issue":"3","key":"2019111807233033700_B24","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1046\/j.1365-2141.2003.04086.x","article-title":"Follicular lymphoma lacking the t(14;18)(q32;q21): identification of two disease subtypes.","volume":"120","author":"Horsman","year":"2003","journal-title":"Br J Haematol"},{"issue":"5908","key":"2019111807233033700_B25","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1126\/science.1165395","article-title":"Genomic loss of microRNA-101 leads to overexpression of histone methyltransferase EZH2 in cancer.","volume":"322","author":"Varambally","year":"2008","journal-title":"Science"},{"issue":"15","key":"2019111807233033700_B26","doi-asserted-by":"crossref","first-page":"9836","DOI":"10.1074\/jbc.M709614200","article-title":"MicroRNA-26a targets the histone methyltransferase Enhancer of Zeste homolog 2 during myogenesis.","volume":"283","author":"Wong","year":"2008","journal-title":"J Biol Chem"},{"issue":"1","key":"2019111807233033700_B27","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/carcin\/bgq209","article-title":"Pathologically decreased miR-26a antagonizes apoptosis and facilitates carcinogenesis by targeting MTDH and EZH2 in breast cancer.","volume":"32","author":"Zhang","year":"2011","journal-title":"Carcinogenesis"},{"issue":"4","key":"2019111807233033700_B28","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/JTO.0b013e318208eb35","article-title":"MicroRNA-101 exerts tumor-suppressive functions in non-small cell lung cancer through directly targeting enhancer of Zeste homolog 2.","volume":"6","author":"Zhang","year":"2011","journal-title":"J Thorac Oncol"},{"issue":"4","key":"2019111807233033700_B29","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1038\/leu.2010.311","article-title":"EZH2 Y641 mutations in follicular lymphoma.","volume":"25","author":"Bodor","year":"2011","journal-title":"Leukemia"},{"key":"2019111807233033700_B30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1747-1028-5-21","article-title":"Chk1 suppressed cell death.","volume":"5","author":"Meuth","year":"2010","journal-title":"Cell Div"},{"issue":"10","key":"2019111807233033700_B31","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/ni1508","article-title":"Genotoxic stress regulates expression of the proto-oncogene Bcl6 in germinal center B cells.","volume":"8","author":"Phan","year":"2007","journal-title":"Nat Immunol"},{"issue":"2","key":"2019111807233033700_B32","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0002-9440(10)63672-3","article-title":"Variations in ATM protein expression during normal lymphoid differentiation and among B-cell-derived neoplasias.","volume":"163","author":"Starczynski","year":"2003","journal-title":"Am J Pathol"},{"issue":"40","key":"2019111807233033700_B33","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.1038\/sj.onc.1204596","article-title":"The role of TCL1 in human T-cell leukemia.","volume":"20","author":"Pekarsky","year":"2001","journal-title":"Oncogene"},{"issue":"4","key":"2019111807233033700_B34","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/labinvest.3780264","article-title":"TCL1 oncogene expression in B cell subsets from lymphoid hyperplasia and distinct classes of B cell lymphoma.","volume":"81","author":"Said","year":"2001","journal-title":"Lab Invest"},{"issue":"2","key":"2019111807233033700_B35","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/S1097-2765(00)00039-3","article-title":"The protooncogene TCL1 is an Akt kinase coactivator.","volume":"6","author":"Laine","year":"2000","journal-title":"Mol Cell"},{"issue":"3","key":"2019111807233033700_B36","doi-asserted-by":"crossref","first-page":"1490","DOI":"10.4049\/jimmunol.182.3.1490","article-title":"T cell leukemia\/lymphoma 1 and galectin-1 regulate survival\/cell death pathways in human naive and IgM+ memory B cells through altering balances in Bcl-2 family proteins.","volume":"182","author":"Tabrizi","year":"2009","journal-title":"J Immunol"},{"issue":"2","key":"2019111807233033700_B37","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1038\/modpathol.2008.148","article-title":"TCL1A expression delineates biological and clinical variability in B-cell lymphoma.","volume":"22","author":"Aggarwal","year":"2009","journal-title":"Mod Pathol"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/20\/5550\/1346019\/zh804611005550.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/118\/20\/5550\/1346019\/zh804611005550.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T12:31:58Z","timestamp":1574080318000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/118\/20\/5550\/29741\/MicroRNA-profiles-of-t1418negative-follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,11,17]]},"references-count":37,"journal-issue":{"issue":"20","published-print":{"date-parts":[[2011,11,17]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2011-06-361972","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,11,17]]}}}